Anti-tumour necrosis factor (TNF) alpha treatment of rheumatoid arthritis (infliximab) selectively down regulates the production of interleukin (IL) 18 but not of IL12 and IL13.
about
Increased circulating levels and salivary gland expression of interleukin-18 in patients with Sjögren's syndrome: relationship with autoantibody production and lymphoid organization of the periductal inflammatory infiltrateMethotrexate as combination partner of TNF inhibitors and tocilizumab. What is reasonable from an immunological viewpoint?Distinct effects of IL-18 on the engraftment and function of human effector CD8 T cells and regulatory T cellsPathophysiological roles for IL-18 in inflammatory arthritisAntibodies against cyclic citrullinated peptide don't decrease after 6 months of infliximab treatment in refractory rheumatoid arthritis.Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvementSynovial tissue interleukin-18 expression and the response to treatment in patients with inflammatory arthritisClinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNF alpha and IL18 but not CXCL12.Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention.Cellular targets of interleukin-18 in rheumatoid arthritis.The role of tumor necrosis factor-alpha in systemic lupus erythematosusInterleukin-18 as a potential therapeutic target in chronic autoimmune/inflammatory conditions.Signalling, inflammation and arthritis: Crossed signals: the role of interleukin-15 and -18 in autoimmunity.Anti-TNF-α agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls.Genetic Markers Predict Primary Non-Response and Durable Response To Anti-TNF Biologic Therapies in Crohn's Disease.Selective antibody activation through protease-activated pro-antibodies that mask binding sites with inhibitory domains.Transcriptional profiling of leukocytes from rheumatoid arthritis patients before and after anti-tumor necrosis factor therapy: A comparison of anti-nuclear antibody positive and negative subsets.Infliximab treatment reduces the serum levels of interleukin-23 in patients with rheumatoid arthritis.Adenoviral delivery of IL-18 binding protein C ameliorates collagen-induced arthritis in mice.[Methotrexate as combination partner of TNF inhibitors and tocilizumab: what is reasonable from an immunological viewpoint?].Felodipine downregulates serum interleukin-18 levels in rats with fructose-induced metabolic syndrome.Etanercept reduces the serum levels of macrophage chemotactic protein-1 in patients with rheumatoid arthritis.Serum macrophage migration inhibitory factor levels are correlated with response to tocilizumab therapy in patients with rheumatoid arthritis.Inhibition of TNF-α protects against hepatic ischemia-reperfusion injury in rats via NF-κB dependent pathway.
P2860
Q24796641-255C8423-D35D-47B6-8495-A91A67D53998Q26824294-ADC30BD1-21B4-409B-8302-60E154538F43Q27438176-11B137E9-037D-4458-AAF3-BDF018CCA499Q28187644-DAEAB86F-4DE3-4EE5-A5DF-3603043B6D5BQ35475541-AB4429E3-7F5F-4401-B3D1-E4F465707964Q35553375-977B9F06-51A1-4353-BDC2-401A8811B884Q35553556-C859C022-B0ED-44F7-8CFC-766CF71D000CQ35555386-BEABF433-A6C6-4EF5-908D-9DDCB2C36772Q35824493-58A60E24-D1C9-4E28-B52E-B19ABDDF8AE6Q36204178-FCD97C2C-3DB3-4EE7-9E8D-330E83EE4850Q36641608-ECD28C10-F739-44C1-8EC5-59BF6D75B084Q36675441-11FE6316-E10A-4772-8160-C17DD8EF6D16Q37214209-AFD351F3-C9C3-49E2-AE7D-5C7B3AD432E2Q37810960-2E07BAC7-1C28-4FA6-912E-F3B4B7916103Q40594199-3DA95ABC-B8D8-4437-B154-D6B012548009Q41044574-AD687345-9898-4611-80E2-F340B78C1059Q42247134-114C36F7-ACB2-479F-BB3B-2962AB02FEF1Q43291006-2347140C-880F-40DE-BDD9-D9EDA885E680Q43882446-78EFEA4F-2363-4338-9FF0-D0A54DFED414Q44444628-68520A97-239A-4D49-9A28-283392DCDED2Q45918376-E54BE86A-BDF2-475E-A51A-CE570F5E7FD6Q47753840-FE834189-C3A3-42D7-879D-ECC96F3CA5A6Q50996608-2C7A278C-FF89-45A9-9870-DBEAA759E3C9Q54238883-3149F839-C43F-4AD3-838A-B06DBC6FB9C7
P2860
Anti-tumour necrosis factor (TNF) alpha treatment of rheumatoid arthritis (infliximab) selectively down regulates the production of interleukin (IL) 18 but not of IL12 and IL13.
description
2002 nî lūn-bûn
@nan
2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Anti-tumour necrosis factor (T ...... ) 18 but not of IL12 and IL13.
@ast
Anti-tumour necrosis factor (T ...... ) 18 but not of IL12 and IL13.
@en
type
label
Anti-tumour necrosis factor (T ...... ) 18 but not of IL12 and IL13.
@ast
Anti-tumour necrosis factor (T ...... ) 18 but not of IL12 and IL13.
@en
prefLabel
Anti-tumour necrosis factor (T ...... ) 18 but not of IL12 and IL13.
@ast
Anti-tumour necrosis factor (T ...... ) 18 but not of IL12 and IL13.
@en
P2093
P356
P1476
Anti-tumour necrosis factor (T ...... ) 18 but not of IL12 and IL13.
@en
P2093
Alessandri C
Bombardieri M
Spinelli FR
P304
P356
10.1136/ARD.61.8.723
P407
P577
2002-08-01T00:00:00Z